About Cel-Sci (NYSEAMERICAN:CVM)
CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:CVM
CUSIPN/A
Phone+1-703-5069460
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-5,432.69%
Return on EquityN/A
Return on Assets-110.07%
Miscellaneous
EmployeesN/A
Outstanding Shares16,500,000
Cel-Sci (NYSEAMERICAN:CVM) Frequently Asked Questions
What is Cel-Sci's stock symbol?
Cel-Sci trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
How were Cel-Sci's earnings last quarter?
Cel-Sci Co. (NYSEAMERICAN:CVM) announced its quarterly earnings results on Monday, February, 12th. The company reported ($0.53) EPS for the quarter. The firm earned $0.11 million during the quarter. View Cel-Sci's Earnings History.
When is Cel-Sci's next earnings date?
Are investors shorting Cel-Sci?
Cel-Sci saw a drop in short interest in the month of March. As of March 29th, there was short interest totalling 664,027 shares, a drop of 26.0% from the March 15th total of 897,860 shares. Based on an average daily volume of 173,399 shares, the short-interest ratio is currently 3.8 days. Currently, 4.2% of the company's stock are sold short.
Who are some of Cel-Sci's key competitors?
Some companies that are related to Cel-Sci include Abzena (ABZA), Scancell (SCLP), Immutep (IMMP), VolitionRX (VNRX), Novus Therapeutics (NVUS), Caladrius Biosciences (CLBS), Opiant Pharmaceuticals (OPNT), Acerus Pharmaceuti (TRLPF), Imprimis Pharmaceuticals (IMMY), Pure Bioscience (PURE), AzurRx BioPharma (AZRX), Arch Therapeutics (ARTH), Proteon Therapeutics (PRTO), Presbia (LENS), Vivus (VVUS), Capricor Therapeutics (CAPR), IntelGenx Technologies (IGXT) and Omnicomm Systems (OMCM).
Who are Cel-Sci's key executives?
Cel-Sci's management team includes the folowing people:
- Mr. Geert R. Kersten, Chief Exec., Financial & Accounting Officer, Treasurer and Director (Age 59)
- Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 67)
- Dr. Eyal Talor, Chief Scientific Officer (Age 62)
- Dr. Daniel H. Zimmerman, Sr. VP of Research - Cellular Immunology (Age 77)
- Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 76)
Has Cel-Sci been receiving favorable news coverage?
Media headlines about CVM stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cel-Sci earned a media sentiment score of 0.17 on Accern's scale. They also assigned headlines about the company an impact score of 45.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Cel-Sci?
Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cel-Sci's stock price today?
One share of CVM stock can currently be purchased for approximately $1.87.
How big of a company is Cel-Sci?
Cel-Sci has a market capitalization of $25.49 million.
How can I contact Cel-Sci?
Cel-Sci's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.
MarketBeat Community Rating for Cel-Sci (CVM)
MarketBeat's community ratings are surveys of what our community members think about Cel-Sci and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cel-Sci (NYSEAMERICAN:CVM) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Cel-Sci in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Cel-Sci (NYSEAMERICAN:CVM) Consensus Price Target History
Cel-Sci (NYSEAMERICAN:CVM) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 10/16/2017 | Dawson James | Reiterated Rating | Neutral | |  |
(Data available from 4/19/2016 forward)
Cel-Sci (NYSEAMERICAN:CVM) Earnings History and Estimates Chart
Cel-Sci (NYSEAMERICAN CVM) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2018 | | | | | | | | |
| 2/12/2018 | Q1 2018 | | ($0.53) | | $0.11 million | View | N/A | |
| 12/29/2017 | Q4 2017 | | ($0.58) | | $0.02 million | View | N/A | |
| 8/9/2017 | Q3 2017 | | ($0.53) | | $0.02 million | View | N/A | |
| 5/10/2017 | Q2 2017 | | ($0.05) | | $0.02 million | View | N/A | |
| 2/9/2017 | Q116 | | $0.01 | | $0.01 million | View | N/A | |
| 12/14/2016 | Q4 2016 | | ($0.25) | | $0.10 million | View | N/A | |
| 8/10/2016 | Q316 | | ($0.03) | | $0.13 million | View | N/A | |
| 5/10/2016 | Q2 | | ($0.07) | | $0.03 million | View | N/A | |
| 2/9/2016 | Q1 2016 | | $0.50 | | $0.02 million | View | N/A | |
| 12/11/2015 | Q4 2015 | | ($2.50) | | ($0.07) million | View | N/A | |
| 8/7/2015 | Q3 2015 | | ($1.50) | | $0.39 million | View | N/A | |
| 5/8/2015 | Q2 2015 | ($0.12) | ($0.17) | $0.10 million | $0.20 million | View | N/A | |
| 2/6/2015 | Q1 2015 | ($0.09) | ($0.11) | $0.07 million | $0.14 million | View | N/A | |
| 12/23/2014 | Q4 2014 | ($2.25) | ($2.75) | $0.04 million | $0.07 million | View | N/A | |
| 8/8/2014 | Q3 2014 | | ($2.75) | | $0.02 million | View | N/A | |
| 5/13/2014 | Q114 | ($0.11) | ($0.24) | $0.02 million | $0.0672 million | View | N/A | |
| 2/11/2014 | Q413 | ($0.11) | ($0.15) | $510.39 million | $0.11 million | View | N/A | |
| 1/2/2014 | Q3 | | ($0.27) | | $0.02 million | View | N/A | |
| 8/9/2013 | Q3 2013 | ($5.00) | ($5.00) | $0.10 million | $0.11 million | View | N/A | |
| 5/14/2013 | Q213 | | ($0.01) | | $0.07 million | View | N/A | |
| 2/8/2013 | Q1 2013 | | ($0.01) | | | View | N/A | |
| 12/14/2012 | Q4 2012 | ($5.00) | ($5.00) | | | View | N/A | |
| 8/9/2012 | Q3 2012 | | ($3.00) | | | View | N/A | |
| 5/10/2012 | Q2 2012 | | ($10.25) | | | View | N/A | |
| 2/9/2012 | Q1 2012 | | ($4.50) | | | View | N/A | |
| 12/23/2011 | Q4 2011 | | ($3.25) | | | View | N/A | |
| 8/9/2011 | Q3 2011 | | ($6.25) | | | View | N/A | |
| 5/16/2011 | Q2 2011 | | ($9.25) | | | View | N/A | |
| 2/10/2011 | Q1 2011 | | ($7.50) | | | View | N/A | |
| 12/13/2010 | Q4 2010 | | ($7.50) | | | View | N/A | |
| 8/16/2010 | Q3 2010 | | ($2.50) | | | View | N/A | |
| 5/17/2010 | Q2 2010 | | ($7.00) | | | View | N/A | |
| 2/16/2010 | Q1 2010 | | $5.00 | | | View | N/A | |
| 1/13/2010 | Q4 2009 | | ($58.50) | | | View | N/A | |
| 8/14/2009 | Q3 2009 | | ($12.75) | | | View | N/A | |
| 5/15/2009 | Q2 2009 | | ($4.00) | | | View | N/A | |
| 8/19/2008 | Q3 2008 | | $5.00 | | | View | N/A | |
| 5/16/2008 | Q2 2008 | | ($7.75) | | | View | N/A | |
| 2/14/2008 | Q1 2008 | | ($5.00) | | | View | N/A | |
| 1/14/2008 | Q4 2007 | | ($2.50) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Cel-Sci (NYSEAMERICAN:CVM) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cel-Sci (NYSEAMERICAN CVM) Insider Trading and Institutional Ownership History
Cel-Sci (NYSEAMERICAN CVM) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Peter R Young | Director | Buy | 6,500 | $1.80 | $11,700.00 | 3,691 | |
| 1/22/2018 | Eyal Talor | Insider | Sell | 8,192 | $2.06 | $16,875.52 | 117,698 | |
| 1/16/2018 | Eyal Talor | Insider | Sell | 1,808 | $2.15 | $3,887.20 | 121,156 | |
| 1/12/2018 | Eyal Talor | Insider | Sell | 101 | $2.15 | $217.15 | 121,156 | |
| 10/17/2017 | Vicente Benjamin Asuncion | Director | Sell | 160,000 | $0.39 | $62,400.00 | | |
| 8/25/2017 | Eyal Talor | Insider | Sell | 769 | $1.91 | $1,468.79 | 118,543 | |
| 8/16/2017 | Eyal Talor | Insider | Sell | 14,019 | $2.61 | $36,589.59 | 131,312 | |
| 10/13/2014 | Geert R Kersten | CEO | Buy | 14,999 | $0.77 | $11,549.23 | | |
| 12/30/2013 | Geert R Kersten | CEO | Buy | 300,000 | $0.60 | $180,000.00 | | |
| 10/9/2013 | Geert R Kersten | Insider | Buy | 8,400 | $0.79 | $6,636.00 | | |
| 6/19/2013 | Peter R Young | Director | Buy | 25,000 | $0.24 | $6,000.00 | | |
| 6/14/2013 | Geert R Kersten | Insider | Buy | 145,120 | $0.24 | $34,828.80 | | |
| 5/20/2013 | Geert R Kersten | CEO | Buy | 40,000 | $0.25 | $10,000.00 | | |
| 5/2/2013 | Geert R Kersten | CEO | Buy | 118,700 | $0.27 | $32,049.00 | | |
| 3/27/2013 | Peter R Young | Director | Buy | 25,000 | $0.23 | $5,750.00 | | |
| 3/26/2013 | Geert R Kersten | CEO | Buy | 348,125 | $0.21 | $73,106.25 | | |
(Data available from 1/1/2013 forward)
Cel-Sci (NYSEAMERICAN CVM) News Headlines
| Source: |
|
Cel-Sci (NYSEAMERICAN:CVM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cel-Sci (NYSEAMERICAN:CVM) Income Statement, Balance Sheet and Cash Flow Statement
Cel-Sci (NYSEAMERICAN CVM) Stock Chart for Thursday, April, 19, 2018
Loading chart…
